ClinicalTrials.gg
CompletedNCT02065557Updated Oct 5, 2020Results posted

Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis

A Phase 3 interventional study of Adalimumab and Placebo in Ulcerative Colitis, sponsored by AbbVie. Completed at 60 sites in 14 countries. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2020-10-05.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
101
Allocation
Randomized
Ages
4 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing adalimumab in Colitis, Ulcerative — 1 open to participants now, 2 under way, none of them phase 3. Adalimumab · Colitis, Ulcerative.

Enrollment
12th of 18
101 · median 152
Started
2014
with 1 other
Phase 3
10 of 18
none open now
Registered
10th of 18
by date
Lead sponsor
4 of 18
AbbVie

Among the 18 studies testing adalimumab in Colitis, Ulcerative, this one is the 12th largest by enrollment, is one of 2 that started in 2014, is one of 10 in phase 3, and was the 10th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

1 of the 18 studies testing adalimumab in Colitis, Ulcerative is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 4 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing adalimumab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The purpose of the study is to demonstrate the efficacy and safety, and to assess the pharmacokinetics of adalimumab administered subcutaneously (SC) in pediatric subjects with moderate to severe ulcerative colitis (UC).

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

Keywords

  • Ulcerative Colitis
  • adalimumab
04

Who can participate

Ages eligible
4 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of UC for at least 12 weeks prior to screening, confirmed by endoscopy with .
  • Active ulcerative colitis with a Mayo Score of 6 - 12 points and endoscopy subscore of 2 - 3 despite concurrent treatment with oral or or both.

Exclusion criteria

Exclusion Criteria:

  • Subject with Crohn's disease (CD) or indeterminate colitis (IC).
  • Current diagnosis of fulminant colitis and/or toxic megacolon.
  • Subjects with disease limited to the rectum (ulcerative proctitis) during the screening endoscopy.
  • Chronic recurring infections or active tuberculosis (TB).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    Adalimumab Induction Standard Dose

    Participants randomized to receive adalimumab 2.4 mg/kg (maximum dose of 160 mg) at Baseline and matching placebo at Week 1, 1.2 mg/kg (maximum dose of 80 mg) at Week 2, followed by 0.6 mg/kg (maximum dose of 40 mg) at Week 4 and Week 6.

    Biological: Adalimumab · Biological: Placebo

  • Experimental
    Adalimumab Induction High Dose

    Participants randomized to receive adalimumab 2.4 mg/kg (maximum dose of 160 mg) at Baseline and at Week 1, 1.2 mg/kg (maximum dose of 80 mg) at Week 2, followed by 0.6 mg/kg (maximum dose of 40 mg) at Week 4 and Week 6.

    Biological: Adalimumab

  • Experimental
    Adalimumab Induction High Dose - Open Label

    (After Amendment 4) participants assigned to open-label adalimumab 2.4 mg/kg (maximum dose of 160 mg) at Baseline and at Week 1, 1.2 mg/kg (maximum dose of 80 mg) at Week 2, followed by 0.6 mg/kg (maximum dose of 40 mg) at Week 4 and Week 6.

    Biological: Adalimumab

  • Placebo comparator
    Maintenance Placebo

    (Prior to Amendment 4) participants demonstrating a clinical response per PMS (defined as a decrease in PMS ≥ 2 points and ≥ 30% from Baseline) at Week 8 randomized to maintenance placebo. Participants were to continue their blinded treatment during the maintenance period until Week 52 unless they had ≥ 2 flares and got open label rescue therapy after the second flare.

    Biological: Adalimumab · Biological: Placebo

  • Experimental
    Adalimumab Maintenance Standard Dose

    Participants demonstrating a clinical response per PMS (defined as a decrease in PMS ≥ 2 points and ≥ 30% from Baseline) at Week 8 randomized to adalimumab maintenance standard dose (0.6 mg/kg \[maximum dose of 40 mg\] every other week). Participants were to continue their blinded treatment during the maintenance period until Week 52 unless they had ≥ 2 flares and got open label rescue therapy after second flare.

    Biological: Adalimumab

  • Experimental
    Adalimumab Maintenance High Dose

    Participants demonstrating a clinical response per PMS (defined as a decrease in PMS ≥ 2 points and ≥ 30% from Baseline) at Week 8 randomized to adalimumab maintenance high dose (0.6 mg/kg \[maximum dose of 40 mg\] every week). Participants were to continue their blinded treatment during the maintenance period until Week 52 unless they had ≥ 2 flares and got open label rescue therapy after second flare.

    Biological: Adalimumab

Interventions

  • BiologicalAdalimumab

    Subcutaneous (SC) injection

    Also known as: Humira

  • BiologicalPlacebo

    Subcutaneous (SC) injection

06

What researchers measure

Primary outcomes

  1. Co-Primary Endpoint 1: Percentage of Participants Who Achieved Clinical Remission as Measured by Partial Mayo Score (PMS) at Week 8 - Induction Period

    The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 sub scores (stool frequency, rectal bleeding and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). A negative change in PMS indicates improvement. Clinical remission was defined as a PMS ≤ 2 and no individual subscore \> 1.

    Time frame: Week 8

  2. Co-Primary Endpoint 2: Percentage of Participants With Clinical Remission Per Full Mayo Score (FMS) at Week 52 in Week 8 Responders Per PMS - Maintenance Period

    The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment). Negative changes indicate improvement. PMS responders are defined as those with a decrease in PMS ≥ 2 points and ≥ 30% from Baseline. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \> 1.

    Time frame: Week 52

Secondary outcomes

  1. Ranked Secondary Endpoint 1: Percentage of Participants With Clinical Response Per FMS at Week 52 in Week 8 Responders Per PMS - Maintenance Period

    The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment). Negative changes indicate improvement. PMS responders are defined as those with a decrease in PMS ≥ 2 points and ≥ 30% from Baseline. Clinical response per FMS is defined as a decrease in FMS ≥ 3 points and ≥ 30% from Baseline.

    Time frame: Week 52

  2. Ranked Secondary Endpoint 2: Percentage of Participants With Mucosal Healing at Week 52 in Week 8 Responders Per PMS - Maintenance Period

    The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment). Negative changes indicate improvement. PMS responders are defined as those participants with a decrease in PMS ≥ 2 points and ≥ 30% from Baseline. Mucosal healing per Mayo endoscopy subscore is defined as a subscore of ≤ 1.

    Time frame: Week 52

  3. Ranked Secondary Endpoint 3: Percentage of Participants With Clinical Remission Per FMS at Week 52 in Week 8 Remitters Per PMS - Maintenance Period

    The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment). Negative changes indicate improvement. PMS remitters are defined as those participants with a PMS ≤ 2 and no individual subscore \> 1. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \> 1.

    Time frame: Week 52

  4. Ranked Secondary Endpoint 4: Percentage of Participants With Corticosteroid-Free Clinical Remission Per FMS at Week 52 in Week 8 Responders Per PMS - Maintenance Period

    The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment). Negative changes indicate improvement. PMS responders are defined as those with a decrease in PMS ≥ 2 points and ≥ 30% from baseline. Among participants receiving systemic corticosteroids at Baseline, corticosteroid-free clinical remission per FMS at Week 52 is defined as having discontinued systemic corticosteroids prior to Week 52 and being in FMS clinical remission at Week 52 (defined as Mayo Score ≤ 2 and no individual subscore \> 1).

    Time frame: Week 52

07

Results

Posted Oct 5, 2020

Participant flow

Prior to Protocol Amendment 4, participants were randomized 3:2 at baseline to adalimumab induction high dose or adalimumab induction standard dose. At Week 8, those demonstrating a clinical response per Partial Mayo Score (PMS) were randomized 2:2:1 to adalimumab maintenance standard dose, adalimumab maintenance high dose, or maintenance placebo.

Induction Period
Participant flow — Induction Period
MilestoneIntegrated Study: Induction Standard Dose (I-SD)Integrated Study: Induction High Dose (I-HD)Integrated Study: Induction High Dose Open Label (I-HD-OL)Integrated Study: Maintenance Placebo (M-PL)Integrated Study: Maintenance Standard Dose (M-SD)Integrated Study: Maintenance High Dose (M-HD)
Started325118000
Enrolled in main study304716000
Enrolled in japan sub-study242000
Completed224316000
Not completed1082000
Withdrew: Withdrawal by subject210000
Withdrew: Lack of efficacy211000
Withdrew: Requires alternative/prohibited therapy111000
Withdrew: Non-responder at week 8440000
Withdrew: Adverse event110000
Maintenance Period
Participant flow — Maintenance Period
MilestoneIntegrated Study: Induction Standard Dose (I-SD)Integrated Study: Induction High Dose (I-HD)Integrated Study: Induction High Dose Open Label (I-HD-OL)Integrated Study: Maintenance Placebo (M-PL)Integrated Study: Maintenance Standard Dose (M-SD)Integrated Study: Maintenance High Dose (M-HD)
Started000123336
Completed000112532
Not completed000184
Withdrew: Requires alternative/prohibited therapy000110
Withdrew: Withdrawal by subject000021
Withdrew: Lack of efficacy000052
Withdrew: Subject non-compliance000001

Outcome measures

PrimaryCo-Primary Endpoint 1: Percentage of Participants Who Achieved Clinical Remission as Measured by Partial Mayo Score (PMS) at Week 8 - Induction Period

The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 sub scores (stool frequency, rectal bleeding and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). A negative change in PMS indicates improvement. Clinical remission was defined as a PMS ≤ 2 and no individual subscore \> 1.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Co-Primary Endpoint 1: Percentage of Participants Who Achieved Clinical Remission as Measured by Partial Mayo Score (PMS) at Week 8 - Induction Period
percentage of participantsMain Study: I-SDMain Study: I-HDMain Study: I-SD + I-HDMain Study: I-HD-OLIntegrated Study (Main + Japan Sub-Study): I-SDIntegrated Study (Main + Japan Sub-Study): I-HDIntegrated Study (Main + Japan Sub-Study): I-SD + I-HDIntegrated Study (Main + Japan Sub-Study): I-HD-OL
Co-Primary Endpoint 1: Percentage of Participants Who Achieved Clinical Remission as Measured by Partial Mayo Score (PMS) at Week 8 - Induction Period43.3 (25.46 to 62.57)59.6 (44.27 to 73.63)53.2 (41.52 to 64.71)68.8 (41.34 to 88.98)40.6 (23.70 to 59.36)58.8 (44.17 to 72.42)51.8 (40.56 to 62.92)66.7 (40.99 to 86.66)
Statistical analysis
  • Main Study: I-SD + I-HD · rejective multiple test procedure · p = < 0.001 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for I-SD+I-HD, then for individual adalimumab dose groups (I-HD, I-SD) against the respective external placebo rate (19.83%))controlling familywise Type I error of 5% in a strong sense
  • Main Study: I-HD · rejective multiple test procedure · p = < 0.001 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for I-SD+I-HD, then for individual adalimumab dose groups (I-HD, I-SD) against the respective external placebo rate (19.83%))controlling familywise Type I error of 5% in a strong sense
  • Main Study: I-SD · rejective multiple test procedure · p = 0.382 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for I-SD+I-HD, then for individual adalimumab dose groups (I-HD, I-SD) against the respective external placebo rate (19.83%))controlling familywise Type I error of 5% in a strong sense
  • Integrated Study (Main + Japan Sub-Study): I-SD + I-HD · rejective multiple test procedure · p = < 0.001 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for I-SD+I-HD, then for individual adalimumab dose groups (I-HD, I-SD) against the respective external placebo rate (19.83%))controlling familywise Type I error of 5% in a strong sense
  • Integrated Study (Main + Japan Sub-Study): I-HD · rejective multiple test procedure · p = < 0.001 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for I-SD+I-HD, then for individual adalimumab dose groups (I-HD, I-SD) against the respective external placebo rate (19.83%))controlling familywise Type I error of 5% in a strong sense
  • Integrated Study (Main + Japan Sub-Study): I-SD · rejective multiple test procedure · p = 0.344 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for I-SD+I-HD, then for individual adalimumab dose groups (I-HD, I-SD) against the respective external placebo rate (19.83%))controlling familywise Type I error of 5% in a strong sense
PrimaryCo-Primary Endpoint 2: Percentage of Participants With Clinical Remission Per Full Mayo Score (FMS) at Week 52 in Week 8 Responders Per PMS - Maintenance Period

The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment). Negative changes indicate improvement. PMS responders are defined as those with a decrease in PMS ≥ 2 points and ≥ 30% from Baseline. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \> 1.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Co-Primary Endpoint 2: Percentage of Participants With Clinical Remission Per Full Mayo Score (FMS) at Week 52 in Week 8 Responders Per PMS - Maintenance Period
percentage of participantsMain Study: M-PLMain Study: M-SDMain Study: M-HDMain Study: M-SD + M-HDIntegrated Study (Main + Japan Sub-Study): M-PLIntegrated Study (Main + Japan Sub-Study): M-SDIntegrated Study (Main + Japan Sub-Study): M-HDIntegrated Study (Main + Japan Sub-Study): M-SD + M-HD
Co-Primary Endpoint 2: Percentage of Participants With Clinical Remission Per Full Mayo Score (FMS) at Week 52 in Week 8 Responders Per PMS - Maintenance Period33.3 (9.92 to 65.11)29.0 (14.22 to 48.04)45.2 (27.32 to 63.97)37.1 (25.16 to 50.31)33.3 (9.92 to 65.11)27.3 (13.30 to 45.52)42.9 (26.32 to 60.65)35.3 (24.08 to 47.83)
Statistical analysis
  • Main Study: M-SD + M-HD · rejective multiple test procedure · p = < 0.001 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for M-SD+M-HD, then for individual adalimumab dose groups (M-HD, M-SD) against the respective external placebo rate (18.37%))controlling familywise Type I error of 5% in a strong sense
  • Main Study: M-HD · rejective multiple test procedure · p = < 0.001 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for M-SD+M-HD, then for individual adalimumab dose groups (M-HD, M-SD) against the respective external placebo rate (18.37%))controlling familywise Type I error of 5% in a strong sense
  • Main Study: M-SD · rejective multiple test procedure · p = 0.382 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for M-SD+M-HD, then for individual adalimumab dose groups (M-HD, M-SD) against the respective external placebo rate (18.37%))controlling familywise Type I error of 5% in a strong sense
  • Integrated Study (Main + Japan Sub-Study): M-SD + M-HD · rejective multiple test procedure · p = < 0.001 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for M-SD+M-HD, then for individual adalimumab dose groups (M-HD, M-SD) against the respective external placebo rate (18.37%))controlling familywise Type I error of 5% in a strong sense
  • Integrated Study (Main + Japan Sub-Study): M-HD · rejective multiple test procedure · p = < 0.001 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for M-SD+M-HD, then for individual adalimumab dose groups (M-HD, M-SD) against the respective external placebo rate (18.37%))controlling familywise Type I error of 5% in a strong sense
  • Integrated Study (Main + Japan Sub-Study): M-SD · rejective multiple test procedure · p = 0.344 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for M-SD+M-HD, then for individual adalimumab dose groups (M-HD, M-SD) against the respective external placebo rate (18.37%))controlling familywise Type I error of 5% in a strong sense
SecondaryRanked Secondary Endpoint 1: Percentage of Participants With Clinical Response Per FMS at Week 52 in Week 8 Responders Per PMS - Maintenance Period

The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment). Negative changes indicate improvement. PMS responders are defined as those with a decrease in PMS ≥ 2 points and ≥ 30% from Baseline. Clinical response per FMS is defined as a decrease in FMS ≥ 3 points and ≥ 30% from Baseline.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Ranked Secondary Endpoint 1: Percentage of Participants With Clinical Response Per FMS at Week 52 in Week 8 Responders Per PMS - Maintenance Period
percentage of participantsMain Study: M-PLMain Study: M-SDMain Study: M-HDMain Study: M-SD + M-HDIntegrated Study (Main + Japan Sub-Study): M-PLIntegrated Study (Main + Japan Sub-Study): M-SDIntegrated Study (Main + Japan Sub-Study): M-HDIntegrated Study (Main + Japan Sub-Study): M-SD + M-HD
Ranked Secondary Endpoint 1: Percentage of Participants With Clinical Response Per FMS at Week 52 in Week 8 Responders Per PMS - Maintenance Period33.3 (9.92 to 65.11)61.3 (42.19 to 78.15)67.7 (48.63 to 83.32)64.5 (51.34 to 76.26)33.3 (9.92 to 65.11)57.6 (39.22 to 74.52)65.7 (47.79 to 80.87)61.8 (49.18 to 73.29)
Statistical analysis
  • Main Study: M-SD + M-HD · rejective multiple test procedure · p = < 0.001 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for M-SD+M-HD, then for individual adalimumab dose groups (M-HD, M-SD) against the respective external placebo rate (26.10%))controlling familywise Type I error of 5% in a strong sense
  • Main Study: M-HD · Chi-squared · p = < 0.001 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for M-SD+M-HD, then for individual adalimumab dose groups (M-HD, M-SD) against the respective external placebo rate (26.10%))controlling familywise Type I error of 5% in a strong sense
  • Main Study: M-SD · Chi-squared · p = 0.008 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for M-SD+M-HD, then for individual adalimumab dose groups (M-HD, M-SD) against the respective external placebo rate (26.10%))controlling familywise Type I error of 5% in a strong sense
  • Integrated Study (Main + Japan Sub-Study): M-SD + M-HD · rejective multiple test procedure · p = < 0.001 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for M-SD+M-HD, then for individual adalimumab dose groups (M-HD, M-SD) against the respective external placebo rate (26.10%))controlling familywise Type I error of 5% in a strong sense
  • Integrated Study (Main + Japan Sub-Study): M-HD · rejective multiple test procedure · p = < 0.001 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for M-SD+M-HD, then for individual adalimumab dose groups (M-HD, M-SD) against the respective external placebo rate (26.10%))controlling familywise Type I error of 5% in a strong sense
  • Integrated Study (Main + Japan Sub-Study): M-SD · rejective multiple test procedure · p = 0.038 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for M-SD+M-HD, then for individual adalimumab dose groups (M-HD, M-SD) against the respective external placebo rate (26.10%))controlling familywise Type I error of 5% in a strong sense
SecondaryRanked Secondary Endpoint 2: Percentage of Participants With Mucosal Healing at Week 52 in Week 8 Responders Per PMS - Maintenance Period

The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment). Negative changes indicate improvement. PMS responders are defined as those participants with a decrease in PMS ≥ 2 points and ≥ 30% from Baseline. Mucosal healing per Mayo endoscopy subscore is defined as a subscore of ≤ 1.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Ranked Secondary Endpoint 2: Percentage of Participants With Mucosal Healing at Week 52 in Week 8 Responders Per PMS - Maintenance Period
percentage of participantsMain Study: M-PLMain Study: M-SDMain Study: M-HDMain Study: M-SD + M-HDIntegrated Study (Main + Japan Sub-Study): M-PLIntegrated Study (Main + Japan Sub-Study): M-SDIntegrated Study (Main + Japan Sub-Study): M-HDIntegrated Study (Main + Japan Sub-Study): M-SD + M-HD
Ranked Secondary Endpoint 2: Percentage of Participants With Mucosal Healing at Week 52 in Week 8 Responders Per PMS - Maintenance Period33.3 (9.92 to 65.11)38.7 (21.85 to 57.81)51.6 (33.06 to 69.85)45.2 (32.48 to 58.32)33.3 (9.92 to 65.11)36.4 (20.40 to 54.88)48.6 (31.38 to 66.01)42.6 (30.72 to 55.23)
Statistical analysis
  • Main Study: M-SD + M-HD · rejective multiple test procedure · p = < 0.001 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for M-SD+M-HD, then for individual adalimumab dose groups (M-HD, M-SD) against the respective external placebo rate (22.03%))controlling familywise Type I error of 5% in a strong sense
  • Main Study: M-HD · rejective multiple test procedure · p = < 0.001 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for M-SD+M-HD, then for individual adalimumab dose groups (M-HD, M-SD) against the respective external placebo rate (22.03%))controlling familywise Type I error of 5% in a strong sense
  • Main Study: M-SD · rejective multiple test procedure · p = 0.382 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for M-SD+M-HD, then for individual adalimumab dose groups (M-HD, M-SD) against the respective external placebo rate (22.03%))controlling familywise Type I error of 5% in a strong sense
  • Integrated Study (Main + Japan Sub-Study): M-SD + M-HD · rejective multiple test procedure · p = < 0.001 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for M-SD+M-HD, then for individual adalimumab dose groups (M-HD, M-SD) against the respective external placebo rate (22.03%))controlling familywise Type I error of 5% in a strong sense
  • Integrated Study (Main + Japan Sub-Study): M-HD · rejective multiple test procedure · p = < 0.001 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for M-SD+M-HD, then for individual adalimumab dose groups (M-HD, M-SD) against the respective external placebo rate (22.03%))controlling familywise Type I error of 5% in a strong sense
  • Integrated Study (Main + Japan Sub-Study): M-SD · rejective multiple test procedure · p = 0.344 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for M-SD+M-HD, then for individual adalimumab dose groups (M-HD, M-SD) against the respective external placebo rate (22.03%))controlling familywise Type I error of 5% in a strong sense
SecondaryRanked Secondary Endpoint 3: Percentage of Participants With Clinical Remission Per FMS at Week 52 in Week 8 Remitters Per PMS - Maintenance Period

The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment). Negative changes indicate improvement. PMS remitters are defined as those participants with a PMS ≤ 2 and no individual subscore \> 1. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \> 1.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Ranked Secondary Endpoint 3: Percentage of Participants With Clinical Remission Per FMS at Week 52 in Week 8 Remitters Per PMS - Maintenance Period
percentage of participantsMain Study: M-PLMain Study: M-SDMain Study: M-HDMain Study: M-SD + M-HDIntegrated Study (Main + Japan Sub-Study): M-PLIntegrated Study (Main + Japan Sub-Study): M-SDIntegrated Study (Main + Japan Sub-Study): M-HDIntegrated Study (Main + Japan Sub-Study): M-SD + M-HD
Ranked Secondary Endpoint 3: Percentage of Participants With Clinical Remission Per FMS at Week 52 in Week 8 Remitters Per PMS - Maintenance Period37.5 (8.52 to 75.51)42.9 (21.82 to 65.98)45.5 (24.39 to 67.79)44.2 (29.08 to 60.12)37.5 (8.52 to 75.51)42.9 (21.82 to 65.98)44.0 (24.40 to 65.07)43.5 (28.93 to 58.89)
Statistical analysis
  • Main Study: M-SD + M-HD · rejective multiple test procedure · p = < 0.001 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for M-SD+M-HD, then for individual adalimumab dose groups (M-HD, M-SD) against the respective external placebo rate (14.79%))controlling familywise Type I error of 5% in a strong sense
  • Main Study: M-HD · rejective multiple test procedure · p = < 0.001 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for M-SD+M-HD, then for individual adalimumab dose groups (M-HD, M-SD) against the respective external placebo rate (14.79%))controlling familywise Type I error of 5% in a strong sense
  • Main Study: M-SD · rejective multiple test procedure · p = 0.292 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for M-SD+M-HD, then for individual adalimumab dose groups (M-HD, M-SD) against the respective external placebo rate (14.79%))controlling familywise Type I error of 5% in a strong sense
  • Integrated Study (Main + Japan Sub-Study): M-SD + M-HD · rejective multiple test procedure · p = < 0.001 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for M-SD+M-HD, then for individual adalimumab dose groups (M-HD, M-SD) against the respective external placebo rate (14.79%))controlling familywise Type I error of 5% in a strong sense
  • Integrated Study (Main + Japan Sub-Study): M-HD · rejective multiple test procedure · p = < 0.001 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for M-SD+M-HD, then for individual adalimumab dose groups (M-HD, M-SD) against the respective external placebo rate (14.79%))controlling familywise Type I error of 5% in a strong sense
  • Integrated Study (Main + Japan Sub-Study): M-SD · rejective multiple test procedure · p = 0.292 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for M-SD+M-HD, then for individual adalimumab dose groups (M-HD, M-SD) against the respective external placebo rate (14.79%))controlling familywise Type I error of 5% in a strong sense
SecondaryRanked Secondary Endpoint 4: Percentage of Participants With Corticosteroid-Free Clinical Remission Per FMS at Week 52 in Week 8 Responders Per PMS - Maintenance Period

The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment). Negative changes indicate improvement. PMS responders are defined as those with a decrease in PMS ≥ 2 points and ≥ 30% from baseline. Among participants receiving systemic corticosteroids at Baseline, corticosteroid-free clinical remission per FMS at Week 52 is defined as having discontinued systemic corticosteroids prior to Week 52 and being in FMS clinical remission at Week 52 (defined as Mayo Score ≤ 2 and no individual subscore \> 1).

Time frame:
Week 52
Reported as:
Number · percentage of participants
Ranked Secondary Endpoint 4: Percentage of Participants With Corticosteroid-Free Clinical Remission Per FMS at Week 52 in Week 8 Responders Per PMS - Maintenance Period
percentage of participantsMain Study: M-PLMain Study: M-SDMain Study: M-HDMain Study: M-SD + M-HDIntegrated Study (Main + Japan Sub-Study): M-PLIntegrated Study (Main + Japan Sub-Study): M-SDIntegrated Study (Main + Japan Sub-Study): M-HDIntegrated Study (Main + Japan Sub-Study): M-SD + M-HD
Ranked Secondary Endpoint 4: Percentage of Participants With Corticosteroid-Free Clinical Remission Per FMS at Week 52 in Week 8 Responders Per PMS - Maintenance Period40.0 (5.27 to 85.34)30.8 (9.09 to 61.43)31.3 (11.02 to 58.66)31.0 (15.28 to 50.83)40.0 (5.27 to 85.34)26.7 (7.79 to 55.10)35.3 (14.21 to 61.67)31.3 (16.12 to 50.01)
Statistical analysis
  • Main Study: M-SD + M-HD · rejective multiple test procedure · p = 0.382 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for M-SD+M-HD, then for individual adalimumab dose groups (M-HD, M-SD) against the respective external placebo rate (24.08%))controlling familywise Type I error of 5% in a strong sense
  • Main Study: M-HD · rejective multiple test procedure · p = 1.000 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for M-SD+M-HD, then for individual adalimumab dose groups (M-HD, M-SD) against the respective external placebo rate (24.08%))controlling familywise Type I error of 5% in a strong sense
  • Main Study: M-SD · rejective multiple test procedure · p = 1.000 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for M-SD+M-HD, then for individual adalimumab dose groups (M-HD, M-SD) against the respective external placebo rate (24.08%))controlling familywise Type I error of 5% in a strong sense
  • Integrated Study (Main + Japan Sub-Study): M-SD + M-HD · rejective multiple test procedure · p = 0.344 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for M-SD+M-HD, then for individual adalimumab dose groups (M-HD, M-SD) against the respective external placebo rate (24.08%))controlling familywise Type I error of 5% in a strong sense
  • Integrated Study (Main + Japan Sub-Study): M-HD · rejective multiple test procedure · p = 0.559 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for M-SD+M-HD, then for individual adalimumab dose groups (M-HD, M-SD) against the respective external placebo rate (24.08%))controlling familywise Type I error of 5% in a strong sense
  • Integrated Study (Main + Japan Sub-Study): M-SD · rejective multiple test procedure · p = 0.815 (Adjusted p-value from a sequentially rejective multiple test procedure, testing co-primary and ranked secondary endpoints 1st for M-SD+M-HD, then for individual adalimumab dose groups (M-HD, M-SD) against the respective external placebo rate (24.08%))controlling familywise Type I error of 5% in a strong sense

Adverse events

Collected over See time frame specifics detailed for each reporting group in their respective descriptions below.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Integrated Study (Main + Japan Sub- Study): I-SD0/32 (0%)5/32 (15.6%)13/32 (40.6%)
Integrated Study (Main + Japan Sub- Study): I-HD0/51 (0%)4/51 (7.8%)16/51 (31.4%)
Integrated Study (Main + Japan Sub- Study): I-HD-OL0/18 (0%)1/18 (5.6%)14/18 (77.8%)
Integrated Study (Main + Japan Sub- Study): M-SD0/33 (0%)5/33 (15.2%)15/33 (45.5%)
Integrated Study (Main + Japan Sub- Study): M-HD0/36 (0%)5/36 (13.9%)20/36 (55.6%)
Integrated Study (Main + Japan Sub- Study): M-PL0/12 (0%)1/12 (8.3%)10/12 (83.3%)
Integrated Study (Main + Japan Sub- Study): Any Adalimumab0/101 (0%)22/101 (21.8%)65/101 (64.4%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventIntegrated Study (Main + Japan Sub- Study): I-SDIntegrated Study (Main + Japan Sub- Study): I-HDIntegrated Study (Main + Japan Sub- Study): I-HD-OLIntegrated Study (Main + Japan Sub- Study): M-SDIntegrated Study (Main + Japan Sub- Study): M-HDIntegrated Study (Main + Japan Sub- Study): M-PLIntegrated Study (Main + Japan Sub- Study): Any Adalimumab
COLITIS ULCERATIVEGastrointestinal disorders2/322/511/183/330/360/1210/101
PSORIASISSkin and subcutaneous tissue disorders0/320/510/180/330/361/120/101
ANAEMIABlood and lymphatic system disorders2/320/510/181/330/360/123/101
GASTROENTERITISInfections and infestations0/320/510/182/330/360/122/101
PERICARDITISCardiac disorders1/320/510/180/330/360/121/101
HEADACHENervous system disorders1/320/510/180/330/360/121/101
LOSS OF CONSCIOUSNESSNervous system disorders1/320/510/180/330/360/121/101
ENTERITISGastrointestinal disorders0/320/510/181/330/360/121/101
ENTERITIS INFECTIOUSInfections and infestations0/320/510/181/330/360/121/101
DYSPEPSIAGastrointestinal disorders0/320/510/180/331/360/121/101
Most frequent other events
Showing 10 of 47
Most frequent other events
EventIntegrated Study (Main + Japan Sub- Study): I-SDIntegrated Study (Main + Japan Sub- Study): I-HDIntegrated Study (Main + Japan Sub- Study): I-HD-OLIntegrated Study (Main + Japan Sub- Study): M-SDIntegrated Study (Main + Japan Sub- Study): M-HDIntegrated Study (Main + Japan Sub- Study): M-PLIntegrated Study (Main + Japan Sub- Study): Any Adalimumab
HEADACHENervous system disorders4/325/514/186/332/362/1219/101
COLITIS ULCERATIVEGastrointestinal disorders2/320/510/183/334/362/1211/101
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations0/323/510/182/334/362/1210/101
EPISTAXISRespiratory, thoracic and mediastinal disorders0/320/510/180/330/362/122/101
NASOPHARYNGITISInfections and infestations2/322/511/183/334/361/1212/101
ABDOMINAL PAINGastrointestinal disorders0/322/512/181/331/361/126/101
OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders1/321/512/182/331/360/127/101
C-REACTIVE PROTEIN INCREASEDInvestigations0/321/510/183/330/360/125/101
ANAEMIABlood and lymphatic system disorders1/323/511/182/331/361/129/101
PHARYNGITISInfections and infestations2/321/511/182/331/361/129/101

Baseline characteristics

Age, Continuous
Age, Continuous(years)Integrated Study (Main + Japan Sub- Study): I-SDIntegrated Study (Main + Japan Sub- Study): I-HDIntegrated Study (Main + Japan Sub- Study): I-HD-OLTotal
Mean14.7 ± 2.6613.8 ± 3.0613.8 ± 2.8214.1 ± 2.90
Sex: Female, Male
Sex: Female, Male(Participants)Integrated Study (Main + Japan Sub- Study): I-SDIntegrated Study (Main + Japan Sub- Study): I-HDIntegrated Study (Main + Japan Sub- Study): I-HD-OLTotal
Female15231351
Male1728550
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Integrated Study (Main + Japan Sub- Study): I-SDIntegrated Study (Main + Japan Sub- Study): I-HDIntegrated Study (Main + Japan Sub- Study): I-HD-OLTotal
White28451588
Black1203
Asian3429
Multiple0011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Integrated Study (Main + Japan Sub- Study): I-SDIntegrated Study (Main + Japan Sub- Study): I-HDIntegrated Study (Main + Japan Sub- Study): I-HD-OLTotal
Hispanic or Latino1214
Japanese2428
No Ethnicity29451589
Full Mayo Score (FMS)
Full Mayo Score (FMS)(score on a scale)Integrated Study (Main + Japan Sub- Study): I-SDIntegrated Study (Main + Japan Sub- Study): I-HDIntegrated Study (Main + Japan Sub- Study): I-HD-OLTotal
Mean7.8 ± 1.227.7 ± 1.257.7 ± 1.097.8 ± 1.20
Partial Mayo Score (PMS)
Partial Mayo Score (PMS)(score on a scale)Integrated Study (Main + Japan Sub- Study): I-SDIntegrated Study (Main + Japan Sub- Study): I-HDIntegrated Study (Main + Japan Sub- Study): I-HD-OLTotal
Mean5.7 ± 1.145.5 ± 1.245.5 ± 1.065.6 ± 1.17
Endoscopy Subscore
Endoscopy Subscore(score on a scale)Integrated Study (Main + Japan Sub- Study): I-SDIntegrated Study (Main + Japan Sub- Study): I-HDIntegrated Study (Main + Japan Sub- Study): I-HD-OLTotal
Mean2.1 ± 0.342.2 ± 0.402.2 ± 0.432.2 ± 0.38
Rectal Bleeding Subscore
Rectal Bleeding Subscore(score on a scale)Integrated Study (Main + Japan Sub- Study): I-SDIntegrated Study (Main + Japan Sub- Study): I-HDIntegrated Study (Main + Japan Sub- Study): I-HD-OLTotal
Mean1.4 ± 0.931.5 ± 0.881.4 ± 0.971.5 ± 0.91

2 further baseline measures are reported on the registry.

08

Study locations

60 sites
  • Childrens Hospital LA /ID# 147452
    Los Angeles, California 90027, United States
  • Univ California, San Francisco /ID# 120901
    San Francisco, California 94143-2204, United States
  • Arnold Palmer Hosp Children /ID# 120898
    Orlando, Florida 32806, United States
  • Emory University Hospital /ID# 121858
    Atlanta, Georgia 30322, United States
  • Children's Ctr Digestive, US /ID# 121855
    Atlanta, Georgia 30342, United States
  • University of Chicago /ID# 120904
    Chicago, Illinois 60637-1443, United States
  • Loyola University Medical Ctr /ID# 120900
    Maywood, Illinois 60153, United States
  • Indiana University /ID# 120908
    Indianapolis, Indiana 46202, United States
  • Massachusetts General Hospital /ID# 124551
    Boston, Massachusetts 02114, United States
  • Boston Childrens Hospital /ID# 147714
    Boston, Massachusetts 02115, United States
  • Mayo Clinic - Rochester /ID# 121056
    Rochester, Minnesota 55905-0001, United States
  • Minnesota Gastroenterology P.A /ID# 120895
    Saint Paul, Minnesota 55114, United States
  • Goryeb Chidlren's Hospital /ID# 121860
    Morristown, New Jersey 07960, United States
  • North Shore University Hospital /ID# 120905
    New Hyde Park, New York 11040, United States
  • Univ Rochester Med Ctr /ID# 127776
    Rochester, New York 14642, United States
  • Multicare Institute for Research and Innovation /ID# 147716
    Tacoma, Washington 98405, United States
  • Womens and Childrens Hospital /ID# 127538
    Adelaide, South Australia 5006, Australia
  • Medizinische Universitat Wien /ID# 120802
    Vienna, Wien 1090, Austria
  • LKH Salzburg and Paracelsus /ID# 123457
    Salzburg, 5020, Austria
  • UZ Brussel /ID# 120798
    Jette, Bruxelles-Capitale 1090, Belgium
  • Cliniques Universitaires Saint Luc /ID# 120797
    Woluwe-Saint-Lambert, Bruxelles-Capitale 1200, Belgium
  • Hosp Univ Enfants Reine Fabiol /ID# 120795
    Brussels, 1020, Belgium
  • London Health Sciences Centre /ID# 127777
    London, Ontario N6A 5A5, Canada
  • Palacky University /ID# 131388
    Olomouc, 779 00, Czechia
  • Univ Hosp, Plzen, CZ /ID# 120813
    Plzen, 305 99, Czechia
  • Petz Aladar Megyei Oktato Korh /ID# 124323
    Gyor, 9023, Hungary
  • Balassa Janos County Hospital /ID# 128474
    Szekszard, 7100, Hungary
  • Soroka Medical Ctr /ID# 147338
    Be'er Sheva, 84101, Israel
  • Assaf Harofeh Medical Center /ID# 147791
    Be'er Ya'akov, 70300, Israel
  • Rambam Health Care Campus /ID# 120827
    Haifa, 3109601, Israel
  • Shaare Zedek Medical Center /ID# 120830
    Jerusalem, 91031, Israel
  • Schneider Childrens Med Ctr /ID# 120821
    Petah Tikva, 4920235, Israel
  • Sheba Medical Center /ID# 124324
    Ramat Gan, 5262100, Israel
  • Kaplan Medical Center /ID# 150245
    Rehovot, 76100, Israel
  • Kurume University Hospital /ID# 125476
    Kurume-shi, Fukuoka 830-0011, Japan
  • Gunma University Hospital /ID# 126345
    Maebashi-shi, Gunma 371-8511, Japan
  • Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital /ID# 124482
    Sapporo-shi, Hokkaido 060-0033, Japan
  • The Hospital of Hyogo College of Medicine /ID# 131665
    Nishinomiya-shi, Hyogo 663-8501, Japan
  • Saiseikai Yokohamashi Tobu /ID# 124486
    Yokohama-shi, Kanagawa 230-0012, Japan
  • Yokohama City Univ Medical Ctr /ID# 147763
    Yokohama, Kanagawa 232-0024, Japan
  • Miyagi Children's Hospital /ID# 125475
    Sendai-shi, Miyagi 989-3126, Japan
  • Saitama Children's Medical Center /ID# 124485
    Saitama-shi, Saitama 330-8777, Japan
  • Juntendo University Hospital /ID# 124536
    Bunkyo-ku, Tokyo 113-8431, Japan
  • National Center for Child Health and Development /ID# 125203
    Setagaya-ku, Tokyo 157-8535, Japan
  • Osaka General Medical Center /ID# 124535
    Osaka, 558-8558, Japan
  • Canterbury District Health Boa /ID# 120837
    Christchurch, 8011, New Zealand
  • Polish Mothers Memorial Hosp /ID# 148497
    Lodz, Lodzkie 93-338, Poland
  • Uni Szpital Dzieciecy w Krakowie /ID# 120915
    Cracow, Malopolskie 30-663, Poland
  • Centrum Zdrowia MDM /ID# 120910
    Warsaw, Mazowieckie 00-635, Poland
  • Gabinet Lekarski Bartosz Korcz /ID# 120916
    Rzeszow, 35-210, Poland
  • Samodzielny Publiczny Szpital /ID# 120839
    Wroclaw, 50-369, Poland
  • Univerzitna nemocnica Martin /ID# 120844
    Martin, Zilinsky Kraj 036 01, Slovakia
  • FN s poliklinikou F.D. Rooseve /ID# 120847
    Banska Bystrica, 974 09, Slovakia
  • Univerzitna Nemocnica Bratislava /ID# 120842
    Bratislava, 821 01, Slovakia
  • Hospital Univ Vall d'Hebron /ID# 120856
    Barcelona, 08035, Spain
  • Hospital Infantil Universitario Nino Jesus /ID# 121862
    Madrid, 28009, Spain
  • The Royal London Hospital /ID# 120861
    London, London, City Of E1 1BB, United Kingdom
  • The Royal Free Hospital /ID# 123142
    London, London, City Of NW3 2QG, United Kingdom
  • Royal Hosp for Sick Children /ID# 120864
    Glasgow, G3 8SJ, United Kingdom
  • Manchester Royal Infirmary, Ma /ID# 120862
    Manchester, M13 9WL, United Kingdom
09

References and documents

Publications

  • Croft NM, Faubion WA Jr, Kugathasan S, Kierkus J, Ruemmele FM, Shimizu T, Mostafa NM, Venetucci M, Finney-Hayward T, Sanchez Gonzalez Y, Bereswill M, Lazar A, Turner D. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study. Lancet Gastroenterol Hepatol. 2021 Aug;6(8):616-627. doi: 10.1016/S2468-1253(21)00142-4. Epub 2021 Jun 19. PubMed 34153231 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2014 to primary completion in Feb 2020, 63 months.

Results were first posted in Oct 2020, 7 months after primary completion.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 63 months is above that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2014
First posted
Feb 19, 2014
StartActual
Oct 13, 2014
Primary completionActual
Feb 7, 2020
CompletionActual
Feb 7, 2020
Results first posted
Oct 5, 2020
Last update
Oct 5, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02065557
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Feb 19, 2014
Start date
Oct 13, 2014
Primary completion
Feb 7, 2020
Completion
Feb 7, 2020
Results posted
Oct 5, 2020
Last update
Oct 5, 2020

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion